Experimental study to develop Src-targeted molecular therapy in small cell lung cancer

小细胞肺癌Src靶向分子治疗的实验研究

• 批准号: 22501044
• 负责人: IGISHI Tadashi
• 金额: $ 2.25万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22501044/
• 关键词: 小細胞肺癌; 分子標的治療; Src

Stem cell factor/c-kit and insulin-like growth factor-I(IGF-I)/IGF-I receptor were detected in small cell lung cancer specimens. In small cell lung cancer cell line, H209 cells, both stem cell factor and IGF-I induced amrubicin resistance. A Src inhibitor, dasatinib, restored the sensitivity to amrubicinin stem cell factor-treated H209 cells. However, dasatinib did not affected IGF-I-induced amrubicinresistance.

在小细胞肺癌标本中检测干细胞因子/c-kit和胰岛素样生长因子- i (IGF-I)/IGF-I受体。在小细胞肺癌细胞系H209细胞中，干细胞因子和igf - 1均可诱导氨柔比星耐药。Src抑制剂达沙替尼恢复了对amrubicinin干细胞因子处理的H209细胞的敏感性。然而，达沙替尼不影响igf -i诱导的氨柔比星耐药。